JP2021514190A5 - - Google Patents

Info

Publication number
JP2021514190A5
JP2021514190A5 JP2020543932A JP2020543932A JP2021514190A5 JP 2021514190 A5 JP2021514190 A5 JP 2021514190A5 JP 2020543932 A JP2020543932 A JP 2020543932A JP 2020543932 A JP2020543932 A JP 2020543932A JP 2021514190 A5 JP2021514190 A5 JP 2021514190A5
Authority
JP
Japan
Prior art keywords
mrna sequence
sequence
mirna
isolated mrna
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020543932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021514190A (ja
Filing date
Publication date
Priority claimed from PCT/US2018/049772 external-priority patent/WO2019051100A1/en
Application filed filed Critical
Priority claimed from PCT/GB2019/050454 external-priority patent/WO2019158955A1/en
Publication of JP2021514190A publication Critical patent/JP2021514190A/ja
Publication of JP2021514190A5 publication Critical patent/JP2021514190A5/ja
Priority to JP2024015220A priority Critical patent/JP2024059656A/ja
Pending legal-status Critical Current

Links

JP2020543932A 2017-09-07 2019-02-19 コード化リボ核酸の器官保護発現および調節のための組成物および方法 Pending JP2021514190A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024015220A JP2024059656A (ja) 2017-09-07 2024-02-02 コード化リボ核酸の器官保護発現および調節のための組成物および方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862632056P 2018-02-19 2018-02-19
US62/632,056 2018-02-19
PCT/US2018/049772 WO2019051100A1 (en) 2017-09-07 2018-09-06 COMPOSITIONS AND METHODS FOR TARGETED CODING ADMINISTRATION, EXPRESSION AND MODULATION OF RIBONUCLEIC ACIDS IN TISSUE
USPCT/US2018/049772 2018-09-06
PCT/GB2019/050454 WO2019158955A1 (en) 2018-02-19 2019-02-19 Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024015220A Division JP2024059656A (ja) 2017-09-07 2024-02-02 コード化リボ核酸の器官保護発現および調節のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2021514190A JP2021514190A (ja) 2021-06-10
JP2021514190A5 true JP2021514190A5 (enExample) 2022-02-17

Family

ID=67619768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020543932A Pending JP2021514190A (ja) 2017-09-07 2019-02-19 コード化リボ核酸の器官保護発現および調節のための組成物および方法

Country Status (7)

Country Link
US (1) US20200376142A1 (enExample)
EP (2) EP3755344A1 (enExample)
JP (1) JP2021514190A (enExample)
CN (1) CN111954535A (enExample)
AU (2) AU2019221826A1 (enExample)
CA (1) CA3091543A1 (enExample)
WO (1) WO2019158955A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201714430D0 (en) 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue
JP7539723B2 (ja) * 2020-02-21 2024-08-26 コンバインド セラピューティクス インコーポレイテッド コード化リボ核酸の器官保護発現及び調節のための組成物並びに方法
CN113583977B (zh) * 2020-04-30 2025-06-06 杭州康万达医药科技有限公司 可受微小rna调控的分离的重组溶瘤痘病毒及其应用
JP2023536844A (ja) * 2020-07-31 2023-08-30 コンバインド セラピューティクス インコーポレイテッド ワクチン接種を改善するための組成物および方法
CN114908089B (zh) * 2021-02-08 2024-03-15 上海细胞治疗集团有限公司 3’utr的构建方法和应用
CA3171589A1 (en) 2021-05-03 2022-11-03 Moritz THRAN Improved nucleic acid sequence for cell type specific expression
EP4241790A1 (en) * 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Expression system for the treatment of cancer
EP4241791A1 (en) * 2022-03-07 2023-09-13 InnaTher Gene Therapy S.à.r.l. Combined gene and radio therapy for the treatment of cancer
CN116334183B (zh) * 2023-02-18 2025-10-21 四川大学华西医院 基于多重信号放大和金属离子选择性识别现象的尿液中双miRNA的检测方法及其应用
CN116240270B (zh) * 2023-03-06 2026-06-26 西北农林科技大学 一种动物驯服行为相关rrm1基因突变体的应用
CN117530932B (zh) * 2024-01-08 2024-04-26 中国药科大学 一种抑制肿瘤生长及肺转移的人工外泌体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009012263A2 (en) * 2007-07-18 2009-01-22 The Trustees Of Columbia University In The City Of New York Tissue-specific micrornas and compositions and uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
CA3285826A1 (en) 2012-02-22 2026-03-02 The Trustees Of The University Of Pennsylvania Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
DK3184641T3 (da) * 2013-10-28 2020-08-03 Univ Of Pittsburgh - Of The Commonwealth System Of Higher Education Onkolytisk hsv-vektor
US20170202979A1 (en) * 2014-07-17 2017-07-20 Modernatx, Inc. Terminal modifications of polynucleotides
WO2016040395A1 (en) * 2014-09-08 2016-03-17 Massachusetts Institute Of Technology Rna-based logic circuits with rna binding proteins, aptamers and small molecules
AU2017212713B2 (en) * 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
RS63625B1 (sr) * 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
GB201714430D0 (en) * 2017-09-07 2017-10-25 Micol Romain Compositions and processes for targeted delivery and expression and modulation of therapeutic components in tissue

Similar Documents

Publication Publication Date Title
Huang et al. Development of molecular mechanisms and their application on oncolytic Newcastle disease virus in cancer therapy
Xu et al. Oncolytic vaccinia virus and cancer immunotherapy
Muthukutty et al. Oncolytic virus engineering and utilizations: cancer immunotherapy perspective
Pol et al. Trial watch: oncolytic viruses for cancer therapy
Zhang et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus
Vacchelli et al. Trial watch: Oncolytic viruses for cancer therapy
JP2020533411A5 (enExample)
Zhu et al. Development and application of oncolytic viruses as the nemesis of tumor cells
Malhotra et al. Oncolytic viruses and cancer immunotherapy
Jebar et al. Progress in clinical oncolytic virus-based therapy for hepatocellular carcinoma
RU2020112990A (ru) Композиции и процессы для направленной доставки, экспрессии и модуляции кодирующих рибонуклеиновых кислот в ткани
EP3566709B1 (en) Therapeutic agents comprising oncolytic vaccinia viruses and nk cells, and uses thereof for drugs for treatment of tumors and/or cancers
IL295724A (en) Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids
Duan et al. Oncolytic Virus‐Driven Biotherapies From Bench to Bedside
CN115624524B (zh) Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用
Apostolidis et al. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
Nisar et al. An extensive review on preclinical and clinical trials of oncolytic viruses therapy for pancreatic cancer
Bahreyni et al. A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy
Ding et al. An Inter‐Supplementary Biohybrid System Based on Natural Killer Cells for the Combinational Immunotherapy and Virotherapy of Cancer
Omole et al. Comprehensive assessment on the applications of oncolytic viruses for cancer immunotherapy
Yuan et al. The investigation of oncolytic viruses in the field of cancer therapy
Kenoosh et al. Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside
CN119736261A (zh) 溶瘤病毒及其应用
Yang et al. The role of mesenchymal stem cells and exosomes in tumor development and targeted antitumor therapies
Wang et al. Oncolytic viruses: a promising therapy for malignant pleural effusion and solid tumors